Nov 13 (Reuters) - Amgen ( AMGN ) said on Wednesday it
does not see any bone safety concerns around the use of its
experimental obesity drug, a day after data from an early-stage
study dragged its stock 7% lower.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini
Ganguli)